Prostate cancer is common but can commonly be cured with surgery, however, this often leads to a loss of erections, because the nerves controlling erections run in the outer coverings of the prostate. Nerve sparing, where the outer layers of the prostate are peeled off, increases post-operative potency, but also increases the risk of cancer being left behind and the need for radiotherapy, which renders the men impotent, even if they had nerve sparing surgery. A new technique called NeuroSAFE incorporates an additional safety check designed to promote nerve sparing without compromising cancer control. During surgery, a pathologist examines the prostate near the nerves to check for exposed cancer. If cancer is found, the nerve tissue is removed so the recurrence risk is similar to when cancer cells are not exposed. The investigators eventual aim is to perform a large scale RCT comparing NeuroSAFE with current UK practice (nerve sparing based on MRI scan, biopsy results and clinical examination). This application is to fund a feasibility study to ensure that men are prepared to be randomised within an RCT, and that the technique can be taught to other UK centres, so allowing participation in the multi-centre RCT. The investigators will gather data to allow us to plan the larger study by defining the primary outcome measure and powering the study based on the size and confidence interval of observed effects. This study is needed because with evidence supporting observation of low risk small cancers, a higher proportion of men undergoing surgery have capsular involvement. The investigators do not have a reliable way to detect cancer which has spread through the capsule of the prostate in whom nerve sparing would cause a positive surgical margin. The NeuroSAFE technique addresses this need and will only be available at participating centres through this trial.